The prevalence of interstitial lung disease (ILD) across connective tissue disorders (CTDs) and its persistent standing as a leading cause of death in patients with CTDs challenge rheumatologists ...
Baylor Medicine’s Interstitial Lung Disease (ILD) program offers specialized and multidisciplinary care. We bring together a unique team of physicians of multiple sub-specialties for patients with a ...
Nerandomilast improved FVC in the FIBRONEER-ILD trial, meeting its primary end point in patients with progressive pulmonary fibrosis. Safety and tolerability results were consistent with previous ...
The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback